

APPENDIX A

Figures 1-10

PhenoSense HIV Entry Assay

Envelope Expression Vector: pHIVenv




Fig. 1A

1/14

HIV-1 Expression Vector: pHIVlucΔU3




Fig. 1B

PhenoSense™ HIV: Cell Assay




Fig. 2

HIV Envelope Expression Strategies




Fig. 2




Fig. 3A

Co-Receptor Tropism Assay Interpretation





Fig. 3B

Entry Inhibitor Susceptibility: Fusion Inhibitor*Fig. 4A*






Fig. 4B

*Fig. 5A*

Entry Inhibitor Susceptibility: CXCR4 Inhibitor



Drug: X4 Inhibitor
Cell: CD4/CXCR4

Fig. 5B









Fig. 6

Target Cell Receptor and Co-Receptor Expression

Fig. 7



**CD4
CXCR4 cells**

**CD4
CCR5 cells**

**CD4
CXCR4+CCR5 cells**

Inhibition By Co-Receptor Antagonists





Fig. 8

Fusion Inhibitor Peptides



Rimsky, et al., J. Virol. 72 (2):986-993

Fig. 9

Patient Virus v. Patient Antibody

Virus Date	Plasma (Antibody) Date									
	9/2/99	11/29/99	2/29/00	5/31/00	8/30/00	11/22/00	2/14/01	5/30/01	9/11/01	
9/2/99	26	219	675	1403	2670	2089	2190	2363	2411	
11/29/99	29	179	1024	2151	3733	3152	2808	2953	3086	
2/29/00	27	35	78	358	1769	1939	2247	3112	4345	
5/31/00	36	67	82	200	795	1078	1371	2208	3375	
8/30/00	19	48	36	64	76	166	556	937	1407	
11/22/00	29	43	64	76	90	119	374	721	1234	
2/14/01	42	65	61	152	117	134	122	289	526	
5/30/01	41	66	82	84	85	113	78	107	296	
9/11/01	42	62	56	62	85	77	55	61	95	
Reference Virus										
NL43	17	138	294	956	1172	953	1584	1868	2143	
JRCSL	24	37	35	60	87	97	105	152	209	

Fig. 10